期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Arginine vasopressin as a target in the treatment of acute heart failure 被引量:7
1
作者 Nisha A Gilotra stuart d russell 《World Journal of Cardiology》 CAS 2014年第12期1252-1261,共10页
Congestive heart failure(CHF) is one of the most common reasons for hospitalization in the United States. Despite multiple different beneficial medications for the treatment of chronic CHF, there are no therapies with... Congestive heart failure(CHF) is one of the most common reasons for hospitalization in the United States. Despite multiple different beneficial medications for the treatment of chronic CHF, there are no therapies with a demonstrated mortality benefit in the treatment of acute decompensated heart failure. In fact, studies of inotropes used in this setting have demonstrated more harm than good. Arginine vasopressin has been shown to be up regulated in CHF. When bound to the V1 a and/or V2 receptors, vasopressin causes vasoconstriction, left ventricular remodeling and free water reabsorption. Recently, two drugs have been approved for use that antagonize these receptors. Studies thus far have indicated that these medications, while effective at aquaresis(free water removal), are safe and not associated with increased morbidity such as renal failure and arrhythmias. Both conivaptan and tolvaptan have been approved for the treatment of euvolemic and hypervolemic hyponatremia. We review the results of these studies in patients with heart failure. 展开更多
关键词 Heart failure Arginine vasopressin antagonist Vaptan HYPONATREMIA Aquaresis VASOPRESSIN
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部